Drug Database
CA

calcifediol (Replidea / JTT 762 / CTAP 101)

✓ Approved

Pharmsynthez · VDR · 小分子

什么是 calcifediol?

calcifediol 是一种小分子,由Pharmsynthez研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)、Oral (PO)。

药物档案

商品名Replidea, JTT 762, CTAP 101
公司Pharmsynthez
药物类别小分子
分子靶点VDR
给药途径Injectable (Others), Intravenous (IV), Oral (PO)
状态Approved

作用机制

分子靶点

calcifediol 作用于 1 个分子靶点:

VDRvitamin D receptor (NR1I1, PPP1R163)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

calcifediol 针对 5 个适应症,涉及 5 个治疗领域。

治疗领域疾病/病症分期
Endocrine disordersHyperparathyroidism secondary✓ Approved
Metabolism and nutrition disordersVitamin D deficiency✓ Approved
Renal and urinary disordersEnd stage renal disease✓ Approved
Infections and infestationsCOVID-19Phase II
Immune system disordersCytokine release syndromePreclinical

相关研究文献

PubMedEye (London, England)2026-11-19

Outcomes of cataract surgery in eyes with vitreomacular traction: a retrospective cohort study.

Kilian Raphael R, Saihan Zubin Z, Maurino Vincenzo V

To evaluate the anatomical and visual outcomes after uncomplicated phacoemulsification in eyes with vitreomacular traction (VMT). This retrospective observational cohort study included consecutive patients with VMT undergoing cataract surgery. Clinical records and optical coherence tomography (OCT) images were reviewed for corrected distance visual acuity (CDVA), axial length, central subfield thickness (CST), VMT configuration and width, intraretinal fluid (IRF), subretinal fluid (SRF), cotton ball sign, postoperative cystoid macular oedema (CMO), VMT release, macular hole formation and subsequent vitrectomy. Multivariable logistic regression was used to assess factors associated with VMT-release. Two hundred and two eyes of 202 patients were included (mean age, 77.1 ± 6.7 years; mean follow-up, 7.3 ± 5.7 months). Postoperative CDVA improved to 0.15 ± 0.16 LogMAR (P < 0.01). CMO developed in 42 eyes (20.8%) and occurred in 15 of 95 eyes receiving ketorolac (15.8%) and 27 of 107 eyes not receiving ketorolac (25.2%, χ² = 2.73, P = 0.099; OR 0.56, 95% CI 0.28-1.12). VMT-release occurred in 14 eyes (6.9%) and macular hole occurred in 6 eyes (3.0%). The presence of IRF, SRF, or cotton ball sign was associated with VMT-release (χ² = 6.83, P = 0.009), whereas age, AL, CST, VMT-morphology and VMT-width were not. Six eyes (3.0%) required secondary vitrectomy. Standalone cataract surgery was associated with improved CDVA and low rates of postoperative macular hole formation and secondary vitrectomy in eyes with VMT. However, postoperative CMO was common, occurring in approximately one-fifth of eyes.

PMID 43052415
阅读全文 →
PubMedJournal of translational medicine2026-11-19

In vitro biological evaluation of a water-soluble hyperbranched β-cyclodextrin nanocarrier for co-delivery of doxorubicin and curcumin.

Samadzadeh Meisam M, Salmanifard Ardestani Mohammad Taha MT, Zarepour Atefeh A, Khosravi Arezoo A et al.

Conventional chemotherapy is often limited by poor aqueous solubility, systemic toxicity, and low bioavailability. To address these limitations, a water-dispersible hyperbranched β-cyclodextrin (HBCD) crosslinked with 1,2,3,4-butanetetracarboxylic acid (BTCA) was developed as a nanocarrier for the co-delivery of doxorubicin (DOX) and curcumin (CUR). HBCD was synthesized under optimized conditions and characterized using complementary physicochemical techniques. DOX and CUR were loaded individually and in combination, and drug release kinetics were evaluated. Biological performance was assessed by hemolysis, cytocompatibility, cellular uptake assessment, apoptosis analyses, anticancer activity, and concentration-dependent drug interaction analysis using SynergyFinder+. The optimized HBCD exhibited favorable physicochemical properties and excellent water solubility. Encapsulation efficiencies in the co-loaded formulation reached 50.8% for DOX and 45.7% for CUR. Drug release showed an initial burst followed by sustained release over 96 h, with kinetics best described by the Korsmeyer-Peppas model. HBCD demonstrated excellent hemocompatibility (<2% hemolysis) and high cytocompatibility toward HDF cells. Drug-loaded formulations produced concentration-dependent cytotoxicity in cancer cell lines. Cellular association and apoptosis analyses confirmed the biological activity of the formulations, while SynergyFinder+ indicated predominantly additive drug interactions with localized concentration-dependent positive interaction regions rather than uniform synergism. BTCA-crosslinked water-dispersible HBCD provides an effective platform for the co-delivery of hydrophilic and hydrophobic anticancer agents, combining efficient drug loading, sustained release, hemocompatibility, and encouraging in vitro biological performance. These findings establish a foundation for future mechanistic, pharmacokinetic, and in vivo studies to further evaluate the translational potential of this delivery system.

PMID 43053162
阅读全文 →
PubMedRNA biology2026-11-19

The venom-gland small RNA transcriptome of the centipede Scolopendra subspinipes mutilans across the venom-release cycle.

Zhao Juan J, Zhao Fang F, Li Yonghong Y, Zhang Wuqiong W et al.

Venom production in centipedes is cyclical, but the small RNA content of the venom gland and its changes across the venom-release cycle have not been described. We sequenced nine small RNA libraries from venom glands of Scolopendra subspinipes mutilans, three at each of three stages: before release, and 0 h and 1 h after electrically induced venom release, and analysed the deposited reads with an open pipeline. miRNAs accounted for 47.6-65.2% of reads. Reads matched 52 conserved miRNA families with arthropod members, including the mandibulate-specific miR-965 and miR-282 and miR-125, which has not been found in the genome of the centipede Strigamia maritima. Reads of 24-30 nt outside known non-coding RNA classes made up 8.4-25.9% of each library; they were biased towards a 5' uridine, showed a strong ping-pong signature and, in a post hoc analysis, came preferentially from transcripts resembling transposable-element proteins, indicating piRNA-like small RNAs in this somatic tissue. No miRNA unit met the differential-abundance criteria of both DESeq2 and edgeR. For 53-65 of 272 miRNA units per comparison, the confidence interval excluded changes of two-fold or more, and simulations indicated that three libraries per stage detect a two-fold change with 14% power. novel-miR34, a predicted novel miRNA whose precursor lies within a transcript annotated as a CAP-superfamily venom allergen, was not significantly altered. A survey of 9,485 NCBI protein records annotated as venom allergens showed that this label is applied across many taxa. These data provide a replicated small RNA resource for a myriapod venom gland.

PMID 43053351
阅读全文 →
PubMedChemphyschem : a European journal of chemical physics and physical chemistry2026-11-19

Bilayer Composition Controls Ferrocyanide Permeability in Soy Lecithin Vesicles.

Cañon J David Chamorro JDC, Luna M Alejandra MA, Correa N Mariano NM, Molina Patricia G PG

Soy lecithin vesicles are attractive nanocarriers owing to their biocompatibility, stability, and low cost. However, controlling the permeability of their bilayer remains a key challenge for their rational use in delivery systems. In this work, we demonstrate that the permeability of soy lecithin vesicles can be systematically tuned by modifying the bilayer composition through the incorporation of dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), and cholesterol. The resulting vesicular systems were characterized by dynamic light scattering (DLS), fluorescence spectroscopy using 6-propionyl-2-dimethylaminonaphthalene (PRODAN) as a probe of the bilayer microenvironment, and electrochemical measurements of potassium ferrocyanide (K4[Fe(CN)6]) release. Changes in lipid composition produced distinct PRODAN responses, consistent with differences in probe localization and bilayer organization, and markedly altered permeability toward encapsulated K4[Fe(CN)6]. The studied formulations spanned a broad range of K4[Fe(CN)6] release behaviors, from substantial retention to complete release at different rates. These results show that relatively small compositional changes provide a practical strategy for tuning the transport of this ionic probe across soy lecithin bilayers. Because permeability depends on the physicochemical nature of the encapsulated species, each prospective cargo must be evaluated in the selected formulation.

PMID 43052681
阅读全文 →
PubMedJournal of drug targeting2026-11-19

Precision-by-design nanotherapeutics: integrating molecular modeling, systems biology, and targeted drug delivery for next-generation personalized medicine.

Li Yanhui Y, Pal Roy Samaresh S, Roy Kalyan K, Kumar Arun A et al.

Nanotherapeutics offer significant potential for targeted drug delivery, controlled release, and molecularly directed treatment, but their development remains challenged by biological heterogeneity, formulation complexity, reproducibility, scale-up, and limited translation from experimental to clinical settings. This review proposes Precision-by-Design (PbD) as an emerging conceptual framework that extends established Quality-by-Design (QbD) principles by incorporating patient- and disease-related biological information into nanotherapeutic development. The framework integrates systems biology, multi-omics data, molecular modelling, computational formulation analysis, and targeted drug-delivery engineering to support biologically informed development decisions. Molecular modelling is considered at both drug-target and drug-carrier levels, including molecular interactions, nanocarrier organisation, stability, biological interfaces, and release mechanisms. Systems biology approaches are discussed for biomarker identification and patient stratification, with potential implications for formulation attributes. A HER2-positive breast cancer example illustrates how molecular information could theoretically guide investigation of target selection and formulation variables, including ligand density, particle size, surface characteristics, drug loading, and release behaviour. Importantly, PbD is not an established clinical formulation methodology, and its proposed benefits require experimental, preclinical, and clinical validation. Future research should emphasise model validation, standardised characterisation, clinically relevant performance measures, regulatory integration, and prospective evaluation of PbD-guided nanotherapeutic development.

PMID 43053491
阅读全文 →
PubMedJournal of orthopaedic surgery and research2026-11-19

Modified percutaneous vertebroplasty with bilateral cannulated screws and staged cement injection for stage I and II Kummell's disease: a mid-to-long term follow-up study.

Wang Huimin H, Li Xiaofeng X, Du Wei W, Sun Xuri X et al.

Kummell's disease (KD) is a delayed post-traumatic vertebral osteonecrosis often complicated by intravertebral vacuum cleft (IVC), cement loosening, and progressive vertebral collapse after conventional percutaneous vertebroplasty (PVP) or kyphoplasty. This study introduces a modified PVP technique using bilateral cannulated screws and staged cement injection for stage I and II KD, and evaluates its safety, feasibility, and mid-to-long-term clinical and radiological outcomes. A total of 38 patients with stage I (n = 18) or stage II (n = 20) KD were retrospectively enrolled. All underwent a modified procedure under local anesthesia: bilateral pedicle placement of headless cannulated screws, transmidline cement delivery using a steerable cannula (Ascend™), and staged injection (high-viscosity cement followed by low-viscosity cement). Clinical outcomes were assessed by visual analogue scale (VAS) and Oswestry Disability Index (ODI). Radiological outcomes included anterior vertebral height (AVH) and Cobb angle. Evaluations were performed preoperatively, at postoperative day 1, 6 months, 12 months, and at final follow-up (mean 17.2 months). Complications were recorded. Significant improvements were observed postoperatively and maintained throughout follow-up. VAS decreased from 6.89 ± 0.87 preoperatively to 1.26 ± 0.61 at final follow-up (P < 0.001). ODI improved from 69.58 ± 9.24% to 17.89 ± 7.03% (P < 0.001). AVH and Cobb angle were both significantly restored at day 1 and remained stable without progressive kyphosis or height loss. Cement extravasation occurred in 15.8% and adjacent vertebral fracture in 5.3%. Stage I patients received larger cement volume than stage II (6.83 ± 1.17 vs. 5.78 ± 1.12 mL, P = 0.008), but final outcomes did not differ between groups (all P > 0.05). The modified PVP combining bilateral cannulated screws, steerable cement delivery, and staged injection is safe and feasible for stage I and II KD. It provides sustained pain relief, functional improvement, and durable vertebral height and kyphosis correction, potentially preventing cement loosening and vertebral re-collapse.

PMID 43053120
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多calcifediol